.svg){kind=spacer}
Details
- Science Corporation has released preliminary results from its PRIMAvera clinical trial, where 38 patients with geographic atrophy, a form of advanced dry age-related macular degeneration, regained significant visual ability using the PRIMA retinal implant system.
- The initiative involved a partnership between Science Corp, noted brain-computer interface researchers, and Professor Frank Holz from the University of Bonn, advancing earlier work developed at Stanford University and by Pixium Vision in France.
- The PRIMA system integrates a wireless photovoltaic chip implanted beneath the retina, specially designed glasses equipped with a camera and projection features, and a pocket processor that sharpens image quality for the 378-pixel implant array.
- After twelve months, trial participants experienced an average improvement of 23 letters, or 4.6 lines, on standardized vision tests, with the top responder gaining 59 letters, roughly 11.8 lines. This progress enabled participants to read, recognize faces, and perform tasks like crossword puzzles.
- In June 2025, Science Corp submitted a CE mark application to European regulators, supplying 60GB of technical evidence for a technology targeting over 8 million global GA patients and 160,000 annual new US cases.
Impact
Science Corp's PRIMA system stands as the first to restore fluent reading ability in individuals with severe vision loss, representing a major step forward for brain-computer interfaces in medicine. By going beyond current treatments that only slow degeneration, PRIMA paves the way for prosthetic vision solutions, placing Science Corp at the forefront of this technology. With CE approval pending, this innovation could reshape care for millions and intensify competition in the global vision restoration field.
